By Donna Loyle, communications specialist, LIMR
Researchers seek patients for a multicenter, randomized clinical trial that aims to determine the safety and effectiveness of using a device called Jetstream Atherectomy (JS) followed by treatment with a drug-coated balloon (DCB). JS is a rotational atherectomy device with active aspiration capacity approved in the United States to treat infrainguinal obstructive peripheral arterial disease.
Eligible participants must have been diagnosed with complex lesions in femoropopliteal arteries with claudication (Rutherford Clinical Category) of 2-4. They also must be able to tolerate antiplatelet therapy, anticoagulants, thrombolytic drugs or any other drug anticipated to be used.
One group of patients receives treatment of their lesions with JS followed by DCB. The other group receives treatment with traditional angioplasty (so called, plain old balloon angioplasty) followed by DCB.
The MLH principal investigator for the JET-RANGER study is Vincent DiGiovanni, DO. The trial is approved for Lankenau Medical Center and Riddle Hospital. For more, visit: www.mainlinehealth.org/research/clinical-trials/jet-ranger